Ocular Therapeutix (OCUL) Change in Accured Expenses (2013 - 2026)
Ocular Therapeutix's quarterly Change in Accured Expenses came in at -$8.4 million in Q1 2026, down 64.06% year-on-year from -$23.5 million in Q1 2025, and down 487.91% quarter-over-quarter from $2.2 million in Q4 2025.
Ocular Therapeutix has reported Change in Accured Expenses for 14 years, with the latest figure at -$8.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 64.06% year-over-year to -$8.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 84.41% YoY), and the FY2025 full-year result was $5.2 million, up 44.26% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$8.4 million, down from $2.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $7.9 million in Q2 2024, with the low at -$14.0 million in Q1 2024.
- Average Change in Accured Expenses over 5 years is $168352.9, with a median of $1.9 million recorded in 2022.
- Year-over-year, Change in Accured Expenses surged 930.32% in 2022 and sank 433.9% in 2024.
- Tracing OCUL's Change in Accured Expenses over 5 years: stood at $1.9 million in 2022, then tumbled by 164.33% to -$1.2 million in 2023, then surged by 437.56% to $4.2 million in 2024, then plunged by 48.26% to $2.2 million in 2025, then sank by 487.91% to -$8.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$8.4 million (Q1 2026), $2.2 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.44 Mn |
| Mar 31, 2026 | -8.44 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 2.84 Mn |
| Mar 31, 2025 | -5.15 Mn |
| Mar 31, 2025 | -5.15 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 7.86 Mn |
| Jun 30, 2024 | 7.86 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Dec 31, 2023 | -1.25 Mn |
| Dec 31, 2023 | -1.25 Mn |
| Sep 30, 2023 | 2.60 Mn |
| Sep 30, 2023 | 2.60 Mn |
| Jun 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 2.05 Mn |
| Mar 31, 2023 | -2.63 Mn |
| Mar 31, 2023 | -2.63 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Sep 30, 2022 | 1.65 Mn |
| Sep 30, 2022 | 1.65 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | -3.05 Mn |
| Mar 31, 2022 | -3.05 Mn |
| Dec 31, 2021 | 188,000.00 |
| Dec 31, 2021 | 188,000.00 |
| Sep 30, 2021 | 2.60 Mn |
| Sep 30, 2021 | 2.60 Mn |
| Jun 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 2.04 Mn |
| Mar 31, 2021 | -1.11 Mn |
| Mar 31, 2021 | -1.11 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Sep 30, 2020 | 2.78 Mn |
| Sep 30, 2020 | 2.78 Mn |
| Jun 30, 2020 | 751,000.00 |
| Jun 30, 2020 | 751,000.00 |
| Mar 31, 2020 | -2.62 Mn |
| Mar 31, 2020 | -2.62 Mn |
| Dec 31, 2019 | 1.17 Mn |
| Dec 31, 2019 | 1.17 Mn |
| Sep 30, 2019 | 1.41 Mn |
| Sep 30, 2019 | 1.41 Mn |
| Jun 30, 2019 | 1.02 Mn |
| Jun 30, 2019 | 1.02 Mn |
| Mar 31, 2019 | -1.89 Mn |
| Mar 31, 2019 | -1.89 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Sep 30, 2018 | 850,000.00 |
| Sep 30, 2018 | 850,000.00 |
| Jun 30, 2018 | 38,000.00 |
| Jun 30, 2018 | 38,000.00 |
| Mar 31, 2018 | -776,000.00 |
| Mar 31, 2018 | -776,000.00 |
| Dec 31, 2017 | -381,000.00 |
| Dec 31, 2017 | -381,000.00 |
| Sep 30, 2017 | 627,000.00 |
| Sep 30, 2017 | 627,000.00 |
| Jun 30, 2017 | 2.47 Mn |
| Jun 30, 2017 | 2.47 Mn |
| Mar 31, 2017 | -153,000.00 |
| Mar 31, 2017 | -153,000.00 |
| Dec 31, 2016 | 1.53 Mn |
| Dec 31, 2016 | 1.53 Mn |
| Sep 30, 2016 | 446,000.00 |
| Sep 30, 2016 | 446,000.00 |
| Jun 30, 2016 | -165,000.00 |
| Jun 30, 2016 | -165,000.00 |
| Mar 31, 2016 | -424,000.00 |
| Mar 31, 2016 | -424,000.00 |
| Dec 31, 2015 | -315,000.00 |
| Dec 31, 2015 | -315,000.00 |
| Sep 30, 2015 | 914,000.00 |
| Sep 30, 2015 | 914,000.00 |
| Jun 30, 2015 | 424,000.00 |
| Jun 30, 2015 | 424,000.00 |
| Mar 31, 2015 | -804,000.00 |
| Mar 31, 2015 | -804,000.00 |
| Dec 31, 2014 | 850,000.00 |
| Dec 31, 2014 | 850,000.00 |
| Sep 30, 2014 | 654,000.00 |
| Sep 30, 2014 | 654,000.00 |
| Jun 30, 2014 | 638,000.00 |
| Jun 30, 2014 | 638,000.00 |
| Mar 31, 2014 | -196,000.00 |
| Mar 31, 2014 | -196,000.00 |
| Dec 31, 2013 | 29,000.00 |
| Dec 31, 2013 | 29,000.00 |
| Sep 30, 2013 | 269,000.00 |
| Sep 30, 2013 | 269,000.00 |